Accurate Biogene is a comprehensive, easy to use life science search engine for life scientists, researchers, graduate students, and health professionals.
Results from a pre-specified pooled analysis of
the RECORD clinical trial program confirmed that the novel oral
anticoagulant Xarelto® (rivaroxaban), taken as one tablet,
once-daily, was superior to enoxaparin-based treatment regimens for the
prevention of venous thromboembolism (VTE) after total knee or hip
replacement surgery with low rates of major bleeding that were not
statistically different from the comparator.
Health
Canada has just approved Xarelto® (rivaroxaban) for the prevention of
venous thromboembolic events (VTE) in patients who have undergone
elective total hip or total knee replacement surgery. This marks the first approval for Xarelto worldwide.
For
the first time in the world, the new oral, once-daily anticoagulant
Xarelto is to be made commercially available to patients in Canada
In
July 2008, the CHMP issued a positive opinion and recommended approval
of rivaroxaban in the EU for the prevention of venous blood clots in
patients undergoing elective total hip or total knee replacement
surgery. A final decision is expected very soon
Xarelto is the most studied oral, direct Factor Xa inhibitor in the world today
Xarelto
is being jointly developed by Bayer HealthCare and Johnson &
Johnson Pharmaceutical Research & Development, L.L.C.
Biomet,
a major manufacturer of artificial hips and knees, said on December 18th that
it had agreed to a $10.9 billion buyout offer from a private investment
consortium.
The bid came from affiliates of the Blackstone Group, Goldman Sachs Capital Partners,
Kohlberg Kravis Roberts & Company and the Texas Pacific Group.
Biomet said the private investment group was also expected to include
Dane A. Miller, a co-founder of Biomet in 1977 and its longtime chief
executive until he resigned in April, citing disagreements with the
board.
If you have some orthopedic news that you would like to share with the Orthogate community, please register/login and submit your news, event, article, announcement or review from the Submit Content menu in your Members Area. Join now .
News 
We subscribe to the HONcode principles. Verify here